Skip to main content
. 2014 Oct;55(10):2103–2112. doi: 10.1194/jlr.M051326

Fig. 3.

Fig. 3.

Effect of alirocumab, atorvastatin, and their combination on plaque morphology. Representative images of HPS-stained atherosclerotic lesions in a cross-section of the aortic root area for the control (A), 3 mg/kg alirocumab (B), 10 mg/kg alirocumab (C), atorvastatin (D), 3 mg/kg alirocumab + atorvastatin (E), and 10 mg/kg alirocumab + atorvastatin (F) groups, respectively, after 18 weeks of treatment.